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Model cell membraneComparative studies of the effect of a short synthetic cationic peptide, pEM-2 (KKWRWWLKALAKK), derived
from the C-terminus of myotoxin II from the venom of the snake Bothrops asper on phospholipid mono- and
bilayers were performed by means of Langmuir Blodgett (LB) monolayer technique, atomic force microscopy
and calcein leakage assay. Phospholipid mono- and bilayers composed of single zwitterionic or anionic
phospholipids as well as lipid mixtures mimicking bacterial cell membrane were used. LB measurements
indicate that the peptide binds to both anionic and zwitterionic phospholipid monolayers at low surface
pressure but only to anionic at high surface pressure. Preferential interaction of the peptide with anionic
phospholipid monolayer is also supported by a more pronounced change of the monolayer pressure/area
isotherms induced by the peptide. AFM imaging reveals the presence of nanoscale aggregates in lipid/
peptide mixture monolayers. At the same time, calcein leakage experiment demonstrated that pEM-2
induces stronger disruption of zwitterionic than anionic bilayers. Results of the study indicate that
electrostatic interactions play a signiﬁcant role in the initial recognition and binding of pEM-2 to the cell
membrane. However, membrane rupturing activity of the peptide depends on interactions other than simple
ionic attraction.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Antimicrobial peptides (AMP) are components of the innate
defence system of many organisms and display potent antimicrobial
activity against a variety of microorganisms by direct action
(disrupting bacterial cell membrane) or by modulating an immune
system response [1–6]. AMP are often alpha helical, composed of 9 to
100 amino acids with a combined molecular weight of 10 kDa or less,
contain an excess positive charge of +2 to +9 arising from mainly
lysine and arginine, and are composed of around 50% hydrophobic
residues [1,7,8].
Although some AMP have been found to interact with intracellular
targets, it is believed that interactions between the peptides and the
cell membrane play an essential role in their mode of action [9]. The
outer leaﬂet of the Gram-negative bacteria contains lipopolysaccha-
ride (LPS) and the single membrane of Gram-positive bacteria
contains acidic polysaccharides [1–6] giving a net negative charge to
the bacterial membrane surface. Moreover, inner leaﬂets of Gram-
negative and Gram-positive bacteria are predominantly composed of
negatively charged phosphatidyl glycerol (PG) and phosphatidyl
ethanolamine (PE). Mammalian cells, on the other hand, contain
predominantly zwitterionic phosphatydilcholine (PC), cholesterolfax: +1 613 520 3749.
l).
ll rights reserved.and sphingomyelin in the outer leaﬂet and negatively charged
phosphatydilserine (PS) in the inner leaﬂet [10]. Due to electrostatic
interactions, positively charged AMP preferentially target negatively
charged cell membranes of bacteria.
Despite the fact that natural AMP have been studied for a
considerable period of time, only four peptides have advanced into
phase 3 clinical trials, but none have been approved for medical use.
This is mainly due to the relatively high toxicity and rapid in vivo
degradation which signiﬁcantly reduces their bioavailability [1–6].
Thus a number of synthetic AMP have been studied and derived to
circumvent the proteolytic susceptibility [1,11]. A series of 10
synthetic peptides was derived from the C-terminus of myotoxin II
of Bothrops asper (KKYRYYLKPLCKK) which is homologous to
catalytically inactive Lys 49 phospholipase A2 [12–14]. In this series
peptides were obtained by substituting one or several tyrosine
residues with tryptophan. A general correlation between the number
of tryptophan substitutions and microbicidal potency was observed.
However, together with high bactericidal activity most of these newly
derived peptides were more cytolytic towards skeletal muscle cells,
thus limiting their potential application in vivo [13]. One of the
derivatives called pEM-2 was obtained through substituting 117, 119
and 120 Tyr with Trp, and 123 Pro and 125 Cys with Ala giving the
sequence KKWRWWLKALAKK. This derivative was found to maintain
high bactericidal [12,13], fungicidal [15] and also antitumor activities
[16] while having reduced toxicity towards eukaryotic cells. The all-D
enantiomer of pEM-2 retains the same bactericidal potency as the
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[12] suggesting a non speciﬁc nature of interactions between the
peptide and the target. In this work the role of hydrophobic and ionic
components in these non speciﬁc interactions was explored by
Langmuir Blodgett (LB) technique, atomic force microscopy (AFM) as
well as calcein leakage assay.
2. Experimental
2.1. Chemicals
1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC), 1,2-Dipal-
mitoyl-sn-Glycero-3-[Phospho-rac-(1-glycerol)] (DPPG), 1,2-Dio-
leoyl-sn-Glycero-3-Phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-
Glycero-3-Phospho-(1′-rac-glycerol) (sodium salt) (DOPG), 1,1′,2,2′
-tetramyristoyl cardiolipin (sodium salt) (CL), and E. coli extract were
purchased fromAvanti Polar Lipids Inc. 1mg/ml solutions of the lipids
were prepared in chloroform (spectroscopy grade, Caledon)/ethanol
(Branton) (3:1, v/v) mixture. Antimicrobial peptide pEM-2 was
synthesized by Gen Script Corporation (N98% purity, with unmodiﬁed
amino and carboxyl ends). Stock solution of the peptide (76.68 μM)
was prepared in phosphate buffer saline (PBS, 0.01 M, 138 mM NaCl,
and 2.7 mM KCl) pH 7.4 (Sigma).
3. Methods
Monolayers were prepared on a Langmuir Blodgett (LB) trough
(NIMA 311-D, Coventry, U.K.) using PBS (∼200 ml) as the subphase.
Monolayers of pEM-2 were prepared by adding appropriate amount
of the peptide stock solution to the subphase to obtain the ﬁnal
peptide trough concentrations between 100 and 842 nM. The trough
was allowed to equilibrate for 25 min and at least 5 compression–
expansion isotherm cycles were performed before the ﬁnal surface
pressure/area isotherm was recorded with a barrier speed of 5 or
20 cm2/min. After that the monolayer was transferred to a freshly
cleaved, hydrophilic 2.5×2.5 cm2 mica sheet by vertical deposition
with a dipping speed of 2 mm/min at the surface pressure of between
7 and 15 mN/m. Transfer ratios of 85–100% were typical.
Phospholipid monolayers were prepared by spreading 30 μl of the
1 mg/ml lipid stock solution at the interface. After the solvent
evaporation (15 min), the monolayer was annealed by performing at
least two compression/expansion cycles.
For the incorporation kinetic experiments, the lipid monolayers
were compressed to 7.5 and 30 mN/m pressure, and the peptide was
injected under the monolayer. Increase of the monolayer surface area
with time at constant surface pressure was recorded.
For the lipid/peptide mixture experiments the lipid monolayers
were expanded and the appropriate amount of the peptide was
injected into the subphase under the lipid monolayer. The systemwas
allowed to equilibrate for 20–30 min to provide uniform pEM-2
distribution in the trough. The pressure/area isotherm of the lipid/
peptide monolayer was recorded and the monolayer was transferred
to a mica sheet for further AFM analysis.
3.1. Calcein leakage assay
For this assay six different model cell membranes were used: pure
DPPC, pure DPPG, Escherichia coli model (DOPE/DOPG 80/20 mol%),
Staphylococcus aureus model (DOPG/CL 55/45 mol%) and Bacillus
subtilis model (DOPE/DOPG/CL 12/84/4 mol%) [17].
Small unilamellar vesicles were prepared by dissolving the
appropriate amount of lipid in chloroform, drying the solvent under
a stream of nitrogen and keeping the sample under vacuum for at least
24 h to ensure complete solvent removal. The obtained lipid ﬁlms
were hydrated in leakage buffer (10 mM Tris–HCl (Bioshop), 150 mM
NaCl, 1 mM EDTA (Bioshop) pH 7.45 in 18.2 MΩ MilliQ water)containing 70 mM calcein (Fluorescein-bis(methyliminodiacetic
acid), Sigma) to obtain the ﬁnal lipid concentration of 1 mg/ml.
Lipid suspensions were sonicated with Misonix ultrasonicator for
2.5 h. Five freeze/thaw cycles were performed to maximize calcein
encapsulation. Free calcein was separated from encapsulated calcein
with a Sephadex G-50 size exclusion column using leakage buffer for
equilibrium and elution (10 ml).
Leakage experiments were carried out using 2 ml of calcein-
containing vesicles diluted 20 times with the leakage buffer on a
Varian Cary Eclipse spectroﬂuorimeter. Measurements were carried
out with excitation and emission wavelength determined for each
experiment (475 nm to 490 nm and 510 nm to 525 nm, respectively).
Excitation and emission slits were 2.5 nm, photomultiplier tube
voltage was 540 V, and integration time was 1.0 s. The baseline
ﬂuorescence (F0) wasmonitored before the addition of the peptide for
30 s. After the peptidewas added the ﬂuorescence signal intensity was
monitored for approximately 15 min or until no further changes
occurred. The ﬁnal ﬂuorescence intensity signal Fwas then measured.
To determine the maximum ﬂuorescence signal corresponding to
complete disruption of the vesicles (FM), 100 μl of 10% triton X-100
(Bioshop) was added to the mixture at the end of the experiment and
ﬂuorescence intensity increase was monitored for 5 min. The leakage
fraction was calculated as: %leakage=[(F−F0)×100%]/(FM−F0).
The concentration of lipid phosphorus was measured by phos-
phate assay [18]. Vesicles with calcein (500 μl) were mixed with
0.1 ml of KNO3 and heated with a Bunsen burner to form potassium
pyrophosphate on ﬂame. After the addition of 0.3 ml of 1 M HCl and
boiling in a water bath for 15 min, potassium pyrophosphate was
hydrolyzed back into phosphate. Then 4.6 ml of 0.22% ammonium
molybdate (Bioshop) and 0.2 ml Fiske–Subbarow reducing agent
were added followed by vigorous stirring. The solutionwas incubating
in a water bath at 40°C for 15 min. Absorption of the signal at 835 nm
was measured. Fiske–Subbarow reagent was prepared by mixing
40 ml of 15% (w/v) sodium bisulfate (Acros Organic), 0.2 g sodium
sulﬁte (Bioshop) and 0.1 g of 1-amino-4-naphtholsulfonic acid (Ricca
Chemical Company). The solution was ﬁltered and stored in the dark
at 4 °C. The phosphate standard solutions were prepared using
sodium phosphate monobasic up to 1 mM in 18.2 MΩ MilliQ water.
3.2. AFM imaging
The topography images of the monolayers were obtained with an
Ntegra (NTMDT, Russia) atomic force microscope in semi contact
mode in air at 23 °C with 512×512 points per image. A 100×100 μm2
scanner (Ntegra) and cantilevers with rotated monolithic silicon tips
(125 μm-long, 40 N/m spring constant Tap 300Al, resonance
frequency 315 kHz, Budget Sensors) were used for all topographic
measurements. The typical scan rate was 0.5 Hz.
4. Results and discussion
4.1. Monolayers of pEM-2
Monolayers of pEM-2 at the air–water interface were obtained by
injecting the peptide into the subphase and allowing the system to
equilibrate. At equilibrium a fraction of the peptide adsorbs at the
interface and forms a monolayer. Fig. 1A shows LB isotherms obtained
for pEM-2 at peptide concentrations up to 842 nM, which is
comparable to minimum microbicidal concentration (MMC) against
a number of bacteria, including E. coli and S. aureus [12]. The surface
pressure increases almost linearly with decreasing surface area till
approximately 15 mN/m. At approximately 15 mN/m the slope of the
isotherm changes indicating that the peptide is lost to the subphase
during the compression [19]. The expansion isotherms do not overlap
with the compression isotherms signaling the loss of pEM-2 into the
subphase above certain pressures. After the complete expansion of the
Fig. 1. (A) Langmuir Blodgett compression–expansion isotherms for pEM-2 monolayer
of different peptide concentrations: -··-·· 400 nM; -·-· 500 nM; ··· 614 nM; — 728
nM;− 800 nM. Compression and expansion isotherms are shown. Hysteresis observed
suggests the loss of pEM-2 from the interface into the subphase during the
compression. (B) Area per nanomole as a function of surface pressure. Average data
calculated for different pEM-2 concentrations are presented.
Fig. 2. Relative increase of the area of DPPG (30 μl, 1 mg/ml), DPPC (30 μl, 1 mg/ml) or
E. coli (20 μl, 1 mg/ml) monolayer compressed to 7.5 mN/m (A) or 30 mN/m (B) as a
function of time after pEM-2 was injected into the subphase. Final pEM-2 concentration
was 400 nM.
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peptide concentration in the trough, higher surface pressure can be
achieved leading to increase in the hysteresis. Such behavior has been
observed for other antimicrobial peptides [19].
In this monolayer experiment pEM-2 was added directly into the
subphase rather than deposited at the interface. This method of
introducing the peptide is more representative of the natural
association phenomena of a peptide with a biological membrane
[19–21]. At the same time, since the amount of the peptide at the
interface is not known it is impossible to calculate the molecular area
for pEM-2 in the monolayer. Instead, the increase in the monolayer
surface area was related to the total peptide concentration in the
trough. Fig. 1B shows the surface area occupied by pEM-2 relative to
the peptide concentration as a function of the surface pressure. In the
4–15 mN/m surface pressure range the area slowly decreases from
0.16 to 0.08 cm2/nM. These values were calculated from the
compression isotherms (Fig. 1A) and represent the upper limit for
the area as the expansion isotherms would give signiﬁcantly lower
values due to the loss of the peptide into the subphase. However,
these numbers provide some quantitative measure of the peptide
surface activity.
The monolayers were transferred onto mica at 7 and 15 mN/m
surface pressures for further AFM analysis. AFM measurements
however did not reveal any aggregation of the peptide at the
substrate (data not shown).
4.2. Kinetics of pEM-2 binding to lipid monolayer
Since most antimicrobial peptides exhibit their activity at the level
of bacterial cell membrane [9], model cell membranes, such asphospholipid monolayers at the air/water interface are often used in
studies of AMP [19–25]. The effect of membrane lipid composition on
binding properties of pEM-2 was studied by conducting insertion
experiments with the peptide injected into the subphase under the
monolayer of zwitterionic DPPC, anionic DPPG phospholipids or E. coli
extract maintained at a constant surface pressure (7.5 or 30 mN/m).
The peptide ﬁnal concentration in the trough was 400 nM, which is
comparable to MMC [12]. Time dependence of the area increase at
constant surface pressure was measured (Fig. 2).
At 7.5 mN/m the peptide readily inserts into monolayers of all
three lipid types with insertion half times around 1000 s (Fig. 2A).
However the degree of the area change is different. For DPPC
monolayer the relative area increase is 20% whereas for DPPG and
for E. coli extract it is almost 35% giving relative molar area change
Δσ/(σ×c) 4.8×10−4 nM−1 for DPPC and 8×10−4 nM−1 for DPPG,
where σ is surface area, Δσ is the area change and c is the peptide
trough concentration.
The insertion experimentwas also performedwith themonolayers
pre-compressed to 30 mN/m (Fig. 2B). After the peptide injection, the
relative area change was found to be 2.5% for DPPG, ∼1% for E. coli
extract and barely any change was observed for DPPC. Relative
molar area change Δσ/(σ×c) was found to be 5.4×10−5 nM−1 for
pEM-2 insertion into DPPG, 2.5×10−5 nM−1 for insertion into E. coli
extract and essentially zero (9.4×10−8 nM−1) for insertion into
DPPC. The insertion half time was ∼500 s which is shorter than for
the 7.5 mN/m experiment.
From this experiment it is clear that the nature of the head group
plays an essential role in the initial pEM-2/membrane recognition and
binding. At low surface pressure of 7.5mN/m the peptide is capable of
incorporating into both anionic and zwitterionic membranes because
of the intrinsic surface activity of the peptide. However, at the
Fig. 3. (A) Effect of different pEM-2 concentrations on the compression isotherms of a
30 μl 1 mg/ml DPPC monolayer. Peptide concentrations: − 0 nM; — 100 nM; -·-·
400 nM; -··-·· 842 nM. (B) Relative area increase at different pressures calculated from
the isotherms shown in panel A. Indicated are ﬁnal concentrations of pEM-2 in the
trough. For comparison surface area of pEM-2 monolayer alone is shown (-+- pEM-2).
2280 A. Won, A. Ianoul / Biochimica et Biophysica Acta 1788 (2009) 2277–2283biologically relevant pressure of 30 mN/m and peptide concentration
of 400 nM, pEM-2 has a much higher afﬁnity to anionic DPPG
membranes and some modest but detectable afﬁnity to the E. coli
membrane which also carries some negative charge. This is caused by
the additional electrostatic attraction between the peptide and the
anionic model cell membrane.
4.3. Interaction of pEM-2 with monolayer of zwitterionic
phospholipid DPPC
LB isotherms for monolayers of zwitterionic phospholipid DPPC in
the presence of pEM-2 were further obtained (Fig. 3A). In this set of
experiments phospholipid monolayers were ﬁrst prepared and the
peptide was injected into the subphase with the monolayer fully
expanded (0 mN/m surface pressure).Fig. 4. AFM topography images of DPPC/pEM-2 monolayers transferred atCompression isotherm for a monolayer of pure DPPC shows a
characteristic liquid expanded–liquid condensed phase transition at
7.5 mN/m (Fig. 3A, solid line) [26]. When pEM-2 is added to the
trough with DPPC monolayer fully expanded, the peptide tends to
adsorb at the air/water interface. Upon further compression the
resulting pEM-2/DPPC mixture monolayer occupies greater area than
the pure DPPC monolayer. With increasing concentration of pEM-2
this total area increases as well (Fig. 3A). The phase transition around
7.5 mN/m is still present when the concentration of the peptide is as
high as 842 nM. At higher surface pressure (26–31 mN/m), surface
areas occupied by the monolayer of DPPC alone and pEM-2/DPPC
mixtures are very similar; suggesting that at this pressure most of the
peptide is lost into the subphase.
The changes in the surface area with respect to the peptide
concentration were further calculated (Fig. 3B). Each curve repre-
sents a relative increase in the area of the monolayer (calculated as:
area of the pEM-2/DPPC mixture minus the area of pure DPPC and
divided by the total concentration of the peptide in the trough) for
different ﬁnal pEM-2 concentrations. For comparison, the Fig. 1B data
for the peptide monolayer alone are presented as -+-. As can be seen
from Fig. 3B, up to 100 nM the increase of surface area upon the
peptide addition varies from 0.2 to 0.02 cm2/nM (Fig. 3B, -♦-) and is
greater or comparable to the area occupied by the peptide alone
(Fig. 3B, line -+-). Therefore, the peptide has slightly higher afﬁnity
to the monolayer of DPPC rather than the air/water interface,
especially at the lower surface pressure.
Fig. 4 shows AFM topography images of pEM-2/DPPC monolayer
deposited onto mica substrate at 30 mN/m for two pEM-2
concentrations: 100 nM and 842 nM. Some small aggregates can be
observed in both cases. There are two kinds of aggregates observed at
100 nM with corresponding heights of 2 nm and 4–6 nm respectively
and lateral dimensions of 30–50 nm. At 842 nM we can only detect
aggregates with the average height of 3–4 nm and lateral size of 30–
50 nm. In both cases the small clusters are organized into larger
irregularly shaped micro-domains. The surface area occupied by the
clusters is similar at both concentrations, which is consistent with LB
data showing a very similar monolayer surface area at 30 mN/m for
100 nM and 842 nM (Fig. 3A). Since no aggregation was observed for
the monolayers of the peptide alone, it is reasonable to assume that
the observed clusters result from the peptide interaction with the
lipid and the formation of some lipid/peptide aggregates. Similar
behavior was recently observed for other AMP [23].4.4. Interaction of pEM-2 with monolayer of anionic phospholipid DPPG
LB isotherms for monolayers of anionic phospholipid DPPG in the
presence of pEM-2 were further obtained (Fig. 5A). Similar to the
previous experiment phospholipid monolayers were ﬁrst prepared30 mN/m. PEM-2 subphase concentrations were 100 nM and 842 nM.
Fig. 5. (A) Effect of increasing pEM-2 concentration on the compression isotherms of a
30 μl 1 mg/ml DPPG monolayer. Peptide concentrations: − 0 nM; — 100 nM; -··-··
200 nM; -·-· 300 nM; and ··· 400 nM. (B) Relative area increase at different pressures
calculated from panel A isotherms. Indicated are ﬁnal concentrations of pEM-2 in the
trough. For comparison surface area of pEM-2 monolayer alone is shown (-+- pEM-2).
Fig. 6. AFM topography images of DPPG/pEM-2 monolayers at 30 mN
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fully expanded (0 mN/m surface pressure).
The compression isotherms of DPPG alone and with increasing
concentration of pEM-2 are presented in Fig. 5A. A characteristic
phase transition can be observed at ∼10 mN/m. DPPG has been
previously shown to exhibit ﬁrst-order phase transition upon
monolayer compression and the pseudo-plateau region seen in the
compression isotherm corresponds to the liquid expanded–liquid
condensed transition [27–29].
With increasing pEM-2 concentration the phase transition around
10 mN/m disappears, the monolayer surface area increases, and a
second transition at 20–25 mN/m appears. In the 100–400 nM
concentration range, the relative increase in the surface area of the
DPPG monolayer (Fig. 5B) was found to be between 0.1 and
0.3 cm2/nM, which is greater than for the DPPC containing monolayer
(Fig. 3B) and in most cases is greater than the area occupied by pEM-2
alone (Fig. 5B, line -+-). At the same time, at a higher surface pressure
of 30 mN/m, the pEM-2/DPPG monolayer surface area is almost
independent of the peptide trough concentration but is considerably
greater than for DPPG alone (Fig. 5A). This indicates that unlike the
DPPC monolayer, a small fraction of the peptide remains in the
monolayer even at high surface pressure. Given the strong positive
charge of the peptide (+6) it is reasonable to assume that the surface
concentration of pEM-2 in DPPGmonolayer is larger than in DPPC due
to electrostatic attraction.
AFM topographymeasurements reveal small nanoscale aggregates
(Fig. 6) in the pEM-2/DPPG monolayers. At lower peptide concen-
tration (100 nM) these aggregates are 1–4 nm in height and 20–60 nm
in diameter and are organized into large micro scale domains.
However, unlike pEM-2/DPPC monolayers, the boundaries of these
domains are smooth and well deﬁned. At this peptide concentration
the liquid expanded–liquid condensed transition is still clearly visible
in the LB isotherm (Fig. 5A)./m. PEM-2 subphase concentrations were 100 nM and 400 nM.
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plateau corresponding to the phase transition in DPPG monolayer
disappears, the topography of the monolayer changes. The size of the
small nanoscale aggregates decreases to 1.5–2 nm in height and
10 nm laterally. The micro scale domains become more circular with
well deﬁned edges. Finally, there are some small holes 0.5 nm deep
observed in the area between the micro scale domains. Similar to
DPPC/pEM-2 monolayer the nanoscale aggregates appear most likely
as a result of the peptide/lipid interactions and contain molecules of
both types. However, unlike DPPC, the nanoscale aggregates in DPPG
monolayer are well separated from each other.
Since the presence of the peptide signiﬁcantly affects the phase
behavior of the lipid monolayer it is possible that the large circular
domains are in fact areas of DPPG in liquid condensed phase whereas
the areas with small holes correspond to the liquid expanded phase.
Similar effect of other peptides on the behavior of lipid monolayers
has been observed before [22]. The different pattern of peptide
distribution as well as higher surface concentration of the peptide in
anionic DPPG as compared with zwitterionic DPPC lipid monolayers
indicates a different nature of interactions between the peptide and
the two phospholipid model cell membranes.
4.5. Calcein leakage assay
Finally, to assess the ability of pEM-2 to rupture bacterial cell
membrane, calcein leakage assay was performed (Fig. 7). Five
different model cell membranes were used: two single lipid
membranes (DPPC and DPPG) and three model mixtures mimicking
gram positive (B. subtilis, S. aureus) and gram negative (E. coli)
bacteria. The amount of calcein release from the vesicles at different
peptide concentrations after approximately 15 min was determined.
Results show similar lytic activity of pEM-2 to DPPC, E. coli, B. subtilis,
and S. aureusmodel vesicles. The calcein leakage experiment indicates
that the ﬂuorescence signal increases rapidly after the peptide
addition and is observed at relatively high peptide to lipid ratios.
The ﬂuorescence intensity increases by around 20% for those model
cell membranes at the peptide/lipid ratio of 1/10 (Fig. 7). At the same
time, effect of the peptide on anionic DPPG vesicles is considerably
weaker: only about 5% calcein release was observed at the pEM-2/
DPPG ratio of 1/10. This observation is quite different from the
monolayer experiments where the peptide showed much higher
afﬁnity to anionic DPPG. Therefore it is possible that interactions other
than electrostatic play the main role in pEM-2 lytic activity.
Interactions of antimicrobial peptides with bacterial cell mem-
branes represent a multi step process which includes: initial
recognition and binding, accompanied by the peptide conformational
transformation, peptide aggregation, insertion into the membrane,Fig. 7. Calcein ﬂuorescence signal increase measured about 15 min after the addition of
pEM-2 into DPPC, DPPG, E. coli model, S. aureus model and B. subtilis model vesicles.and ﬁnally disruption of cell membrane [1–6,30,31]. LB monolayer
surface tension measurements allowed us to monitor the initial step
of peptide binding. Even though the kinetics of the reaction is limited
by peptide diffusion in the trough, the degree of peptide binding to the
monolayer depends on the initial peptide/membrane interactions. It
is conceivable that for this initial recognition and binding step, the
nature of the lipid headgroup rather than other membrane properties
(such as thickness and lateral mobility) plays the determining role.
Therefore in this context LB measurements represent a fairly good
model of this initial step and indicate that electrostatic interactions
contribute considerably to this process [25].
On the other hand calcein leakage assay monitors the ﬁnal step of
the AMP/membrane interactions: formation of pores and/or mem-
brane rupture. In the experiment the degree of membrane disruption
is estimated from the relative amount of calcein released outside the
vesicles. It appears that membrane rupturing ability of pEM-2 does
not correlate with the membrane charge, at least for the model
membranes used in the present study, suggesting that electrostatic
interactions might not play such a critical role in pEM-2's ability to
rupture the membrane [13].
Therefore, although the initial recognition and binding of pEM-2 is
driven by electrostatic interactions the membrane lytic activity of the
peptide is governed by other interactions such as hydrophobic and
depends strongly on the bacterial membrane composition and
physico chemical properties. This conclusion is supported by the
correlation between the number of Trp residues and the bactericidal
activity of other derivatives similar to pEM-2 [13]. With increasing
number of Trp residues from 1 to 3, bactericidal potency of the
peptides was found to increase, suggesting that hydrophobic inter-
actions are critical for membrane damage [13]. This is also consistent
with previous studies of other antimicrobial peptides [32]. For
example, although the membrane charge was found to play a
signiﬁcant role in the rates of the cell-penetrating peptide transportan
binding to the cell membrane, dye efﬂux occurred at about the same
rate from charged and uncharged vesicles [30,33].
Recent studies of pEM-2 by UV resonance Raman spectroscopy
demonstrated that in a membrane mimicking environment the
peptide changes its conformation [34] and likely folds into an α
helical amphipathic structure on the membrane surface. Since pEM-2
is a relatively short peptide it is unlikely that the peptide forms
permanent pores in the membrane. Besides, calcein leakage is
observed at relatively large peptide/lipid ratios. For these reasons, a
carpet mechanism or the recently proposed mechanisms based on
interfacial activity [31,35] of the peptide are the most likely
mechanisms of pEM-2 action in DPPC, E. coli, B. subtilis, and S. aureus
models, but not in DPPG.More support for this hypothesis comes from
the peptide's ability to induce the formation of nanoscale aggregates
in phospholipid monolayers. Lateral organization of these aggregates
strongly depends on the membrane composition and is different for
DPPC and DPPG models. It is not clear at the moment if similar
aggregates occur at the bacterial cell membrane. Further microscopic
investigations of pEM-2 interactions with phospholipid bilayers will
help to establish these mechanisms in more details.
5. Conclusion
In this work we demonstrated that a short synthetic antimicrobial
peptide derived from the C-terminus of myotoxin II from the venom
of the snake Bothrops asper has greater afﬁnity to anionic monolayer
leading to higher peptide surface concentration in anionic rather than
in zwitterionic monolayer. At the same time, peptide lytic activity
appears to be strongly dependent on the model cell membrane
composition. This suggests that although electrostatic interactions
play a major role in the initial recognition and membrane binding of
the peptide, it is rather the membrane lipid composition and
hydrophobic interactions that determine pEM-2 lytic activity.
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